New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
13:25 EDTJAZZ, JAZZ, JAZZ, SLXP, SLXP, SLXPLeerink's specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gerberry discusses the prospects for Jazz Pharmaceuticals/Sigma Tau's Defibrotide approval in the U.S., and provides an assessment of challneges facing two key specialty pharma controversies: Defibrotide and Relistor on an Analyst/Industry conference call to be held on February 27 at 2 pm.
News For JAZZ;SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
09:20 EDTJAZZCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 20, 2015
14:32 EDTJAZZPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use